A relationship between genetic variants in the adenosine biosynthesis pathway and outcomes of MTX treatment in patients with RA and JIA was also reported; polymorphisms in the AMPD1, ATIC, and ITPA genes were associated with good clinical response to MTX treatment [201,202,203]. This evidence concerns the gene ATIC and rheumatoid arthritis.